Compare Byrna Technologies Inc (BYRN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs IDEXX Laboratories, Inc. — how do they compare? Byrna Technologies Inc trades at $3.62 (market cap $80.33M), while IDEXX Laboratories, Inc. trades at $556.61 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 530.9× Byrna Technologies Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BYRN | IDXX | |
|---|---|---|
Market Cap | $80.33M | $42.65B |
Sector | Technology | Health |
52-Week High | $27.63 | $766.68 |
52-Week Low | $3.54 | $514.61 |
Enterprise Value | $71.94M | $43.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $3.82, down 1.16% today, with a bearish technical signal from moving averages. Recent Q2 2026 results showed a significant miss with a $0.44 EPS loss versus -$0.10 expected, amid a 42.5% revenue decline. The company is undergoing a marketing reset and acquired HERO Defense Systems to expand its product portfolio. Net income margin turned negative at -3.39% for 2026, though gross margin remains strong at 52.51%.
Outlook is cautious due to execution risks in sales turnaround efforts. Analyst consensus is bullish with 71% buy ratings, but near-term challenges in e-commerce traffic and conversion pose headwinds. The stock's valuation appears reasonable with P/S of 0.76, but profitability concerns and ongoing legal investigations present substantial risks for investors.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
